Hepavitron

The virucidal and hepato-protective effect of Hepavitron was studied in patients with chronic hepatitis B (CHB), chronic hepatitis C (CHC), Alcoholic liver disease and in patients with liver cirrhosis.

One hundred twenty one patients with serologically confirmed chronic hepatitis C were treated for 48 weeks with Hepavitron. 74 (61%) patients became PCR negative, in 36 (29%) patients, HCV RNA was reduced by over 70 % and needed further therapy for six months to become PCR negative, whereas, 11 (9%) patients were lost to follow-up. The other primary outcome parameter measured was the rate of alanine aminotransferase (ALT) normalization after 12 weeks, which was achieved in 108 (89 %) patients. Secondary parameters included the course of subjective symptoms associated with CHC (fatigue, abdominal discomfort, depression, and dyspepsia), which was significantly reduced from baseline.

In another study, Hepavitron was given to 100 patients with Chronic Hepatitis B (CHB) for 48 weeks. Hepatitis B was removed in 68 patients , whereas, virus load was decreased by more than 70% in the remaining 19 patients. 13 patients were lost to follow-up.